GoPath Diagnostics has obtained a clinical laboratory license from the New York State Department of Health, allowing the company to perform its ProstateNow™ test in addition to its existing Histopathology and Oncology – Molecular and Cellular Tumor Markers testing. ProstateNow™ is a pioneering genetic test that can help individuals determine their risk of developing prostate cancer through Rare Pathogenic Mutations (RPMs) and Genetic Risk Score (GRS) assessment.
CHICAGO, April 6, 2023 /PRNewswire-PRWeb/ -- GoPath Diagnostics, a leading innovative molecular diagnostic company, is proud to announce that they have recently earned a clinal laboratory license that grants authorization from the New York State Department of Health to perform its ProstateNow™ test, in addition to already approved, Histopathology and Oncology – Molecular and Cellular Tumor Markers testing. ProstateNow™ is a cutting-edge genetic test that helps individuals determine their risk of developing prostate cancer.
ProstateNow™ is the only germline test that includes both Rare Pathogenic Mutations (RPMs) & Genetic Risk Score (GRS) for a comprehensive assessment of inherited risk for prostate cancer. To learn more about this groundbreaking test, please visit the following website: https://geneticsnow.com/prostatenow
"We are very excited to have expanded our New York State License approval to now offer ProstateNow™, as it represents a significant milestone in our growth as a company," says Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics. "This enhancement enables GoPath to better serve healthcare providers and patients in New York through our comprehensive suite of services, further bolstering our commitment to providing top-notch healthcare services."
About GoPath Diagnostics
GoPath Diagnostics specializes in molecular, genetics, anatomic pathology, hematopathology, cytology, and digital pathology services. With advanced technologies and an experienced team of laboratory professionals, GoPath Diagnostics provides accurate, reliable, and timely test results to enable clinical healthcare providers to make informed treatment decisions and to empower pathologists by enhancing their molecular and digital capabilities.
For more information about GoPath Diagnostics and its laboratory testing services, please visit the company's website at http://www.gopathdx.com
Media Contact
Edgar Castellanos, GoPath Diagnostics, 1 855-467-2849, [email protected]
SOURCE GoPath Diagnostics
Advertisement
CHICAGO, April 6, 2023 /PRNewswire-PRWeb/ -- GoPath Diagnostics, a leading innovative molecular diagnostic company, is proud to announce that they have recently earned a clinal laboratory license that grants authorization from the New York State Department of Health to perform its ProstateNow™ test, in addition to already approved, Histopathology and Oncology – Molecular and Cellular Tumor Markers testing. ProstateNow™ is a cutting-edge genetic test that helps individuals determine their risk of developing prostate cancer.
Advertisement
ProstateNow™ is the only germline test that includes both Rare Pathogenic Mutations (RPMs) & Genetic Risk Score (GRS) for a comprehensive assessment of inherited risk for prostate cancer. To learn more about this groundbreaking test, please visit the following website: https://geneticsnow.com/prostatenow
"We are very excited to have expanded our New York State License approval to now offer ProstateNow™, as it represents a significant milestone in our growth as a company," says Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics. "This enhancement enables GoPath to better serve healthcare providers and patients in New York through our comprehensive suite of services, further bolstering our commitment to providing top-notch healthcare services."
About GoPath Diagnostics
GoPath Diagnostics specializes in molecular, genetics, anatomic pathology, hematopathology, cytology, and digital pathology services. With advanced technologies and an experienced team of laboratory professionals, GoPath Diagnostics provides accurate, reliable, and timely test results to enable clinical healthcare providers to make informed treatment decisions and to empower pathologists by enhancing their molecular and digital capabilities.
For more information about GoPath Diagnostics and its laboratory testing services, please visit the company's website at http://www.gopathdx.com
Media Contact
Edgar Castellanos, GoPath Diagnostics, 1 855-467-2849, [email protected]
SOURCE GoPath Diagnostics
